Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IPS Extends Global Reach with Local Brazil Office

Published: Friday, November 09, 2012
Last Updated: Friday, November 09, 2012
Bookmark and Share
IPS-Integração de Projetos e Serviços accommodates clients growing needs in South America.

IPS-Integrated Project Services has announced the launch of IPS Integração de Projetos e Serviços.

With a new office in Brazil, IPS enhances its ability to support and accommodate clients growing needs in emerging markets.

IPS-Integração de Projetos e Serviços will operate under the leadership of Francisco Paula Santos, a native of Brazil and an industry executive with extensive experience managing and leading global efforts for major pharmaceutical companies such as Bristol-Myers Squibb (BMS) and Wyeth.

At BMS, he was Vice President of Latin America Technical Operations where he oversaw all operations for Latin Americas.

As General Manger of IPS-Integração de Projetos e Serviços, Mr. Santos will be responsible for the strategic direction and growth of the office in Brazil.

“With a rapidly growing economy, and as the world’s fifth largest country, the Brazil market offers a great deal of opportunity for IPS and our clients,” said Dave Goswami, PE, Chief Executive Officer and Managing Director, IPS.

Goswami continued, “As more and more of our multinational clients are opening facilities in Brazil, as well the local companies intend to construct and/or upgrade its facilities, it is essential for IPS to have a local presence. Our Brazil office will enable us to continue to provide clients with innovative and cost effective business solutions and our superior technical expertise that they have come to expect from our IPS team and brand.”

“Our venture into this region supports our long-term growth strategy and our mission and vision of being the knowledge leaders of choice by helping our clients succeed,” continued Goswami.

“We are excited to have a local presence in Brazil and are confident that Francisco and our local team will deliver the IPS brand in this region and will be able to help our clients maximize their growth potential globally.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!